SGEN

Seagen Inc. Common Stock
SGEN
Market cap $43.2B

Delisted

SGEN was delisted on the 13th of December, 2023.

Back to rankings

About: Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Employees: 3,256

Healthcare Drug Manufacturers - General

Financial journalist opinion

Two Brothers, a Big Biotech Bet and an $8 Billion Payout

Investors in a hedge fund from Baker Bros. Advisors recently received one of the largest windfalls ever following Pfizer's purchase of Seagen.

Two Brothers, a Big Biotech Bet and an $8 Billion Payout

Pfizer: Seagen Acquisition Starting To Bear Fruit

Pfizer's share price has stabilized since the company provided 2024 revenue and EPS guidance in late 2023. The success of Adcetris in a trial for relapsed/refractory DLBCL is a positive step for Pfizer's oncology pipeline and the first win since the Seagen acquisition closed. Pfizer's long-term growth strategy in oncology, including the Seagen acquisition, is expected to contribute significantly to revenue growth in the coming years.

Pfizer: Seagen Acquisition Starting To Bear Fruit

Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition

Pharma giant Pfizer, fresh off its $43 billion acquisition of Seagen, said it will shut down construction on a new 270,000 square-foot manufacturing facility Seagen was building north of Seattle near its headquarters.

Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition

Pfizer CEO doubles down on 2024 guidance, talks Seagen buy

Pfizer (PFE) reported fourth-quarter earnings on Tuesday morning that beat. Wall Street expectations.

Pfizer CEO doubles down on 2024 guidance, talks Seagen buy

Cramer names biopharma companies to watch as industry mergers start to pile up

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

5 Biotech Acquisition Targets To Accumulate In 2024

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

Pfizer Completes Acquisition of Seagen

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. “Cancer remains a leading cause of death, and one in three people in the U.S. will rec.

Pfizer Completes Acquisition of Seagen

How Pfizer's $43B acquisition of Seagen may impact Seattle and broader biotech market

Editor's note: William Canestaro is managing director at Seattle venture capital firm WRF Capital and leads the biotechnology investment team.

How Pfizer's $43B acquisition of Seagen may impact Seattle and broader biotech market

Proactive Investors

Pfizer guides for US$61.5bn sales from Covid-19, Paxlovid, Seagen

Pfizer Inc (NYSE:PFE) said today that it is expecting $58.5 billion to $61.5 billion of sales in 2024 from Covid-19 vaccines, antiviral medicine Paxlovid and Seagen, with deal for the latter cancer drug company imminent. This is higher than its legacy 2024 guidance and slightly above the guidance it gave in October for 2023 sales.

Pfizer guides for US$61.5bn sales from Covid-19, Paxlovid, Seagen

Investors Business Daily

Pfizer's Tumble Steepens As Seagen Guidance Update Disappoints

Pfizer's updated 2024 revenue figures, including Seagen, undercut the consensus target.

Pfizer's Tumble Steepens As Seagen Guidance Update Disappoints

See News Rankings

Charts implemented using Lightweight Charts™